Exploiting ETH Zurich research, Micreos is working on a clinical platform that enables the targeted killing of unwanted bacteria only.

Micreos, a Netherlands-based endolysin platform developer using research from ETH Zurich, raised €32m ($37.5m) in funding from undisclosed investors yesterday. Micreos is working on technology that enables the targeted killing of unwanted bacteria only. The approach relies on endolysins – hydrolytic enzymes that can attack specific bacteria while leaving the remainder of the microbiome intact…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.